⚕ GalenOps field
←

SITE014-0391

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-06-24

AEs
6
Serious
1
Dropout signal
–

Adverse events

severe assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-28 (study day 23); relationship: not assessed

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-04 (study day 30); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-05 (study day 62); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-11 (study day 98); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-09 (study day 157); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 164); relationship: not assessed

Data queries

No data queries.